Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + cisplatin + paclitaxel is a combination chemotherapy regimen used primarily for the treatment of advanced or metastatic cancers, including non-small cell lung cancer (NSCLC) and biliary tract cancers. Each component has a distinct mechanism of action: - Gemcitabine is an antimetabolite that inhibits DNA synthesis by incorporating into DNA and inhibiting ribonucleotide reductase. - Cisplatin is a platinum-based compound that forms DNA crosslinks, leading to apoptosis. - Paclitaxel stabilizes microtubules and prevents their depolymerization, thereby inhibiting cell division. This combination has demonstrated feasibility and efficacy in clinical trials for advanced NSCLC with improved response rates and quality of life compared to historical controls. It is also being investigated in other solid tumors such as biliary tract cancer[2][5][3].
- Brand names
- Abraxane
- Other names
- Gem-Cis-Pac regimenGemcitabine-based chemoradiotherapy
02
Targets
TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on gemcitabine + cisplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + paclitaxel.